Paper Details

  1. Home
  2. Paper Details

Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.

Author: BokemeyerBernd, DomènechEugeni, HowaldtStefanie, MartinezNicholas, SchmidtCarsten

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ferric maltol achieved clinically relevant increases in hemoglobin but did not show noninferiority to ferric carboxymaltose at week 12. Both treatments had comparable long-term effectiveness and were well tolerated.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Iron-deficiency anemia is common in inflammatory bowel disease, requiring oral or intravenous iron replacement therapy. Treatment with standard oral irons is limited by poor absorption and gastrointestinal toxicity. Ferric maltol is an oral iron designed for improved absorption and toler...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889281/

データ提供：米国国立医学図書館（NLM）

Iron Deficiency Anemia: A Tale of Two Iron Treatments

Iron deficiency anemia is a common problem, especially for those with inflammatory bowel disease. This study explores the effectiveness of two iron treatments: oral ferric maltol and intravenous ferric carboxymaltose. The research team designed a randomized controlled noninferiority trial to compare the efficacy of these treatments. They found that while both treatments resulted in significant improvements in hemoglobin levels, oral ferric maltol did not meet the criteria for noninferiority compared to intravenous ferric carboxymaltose at 12 weeks. However, both treatments demonstrated comparable long-term effectiveness for hemoglobin and ferritin levels over 52 weeks. This study highlights the importance of considering both short-term and long-term effects of treatments when evaluating their overall effectiveness.

Long-Term Effectiveness Matters

The study reveals that while intravenous ferric carboxymaltose might provide quicker results in the first few weeks, oral ferric maltol demonstrates comparable long-term efficacy. This emphasizes the need to consider the complete picture when choosing a treatment for iron deficiency anemia.

Navigating Iron Deficiency Anemia

This study reminds us that choosing the right treatment for iron deficiency anemia depends on a range of factors. While intravenous ferric carboxymaltose might be a faster solution, oral ferric maltol offers a comparable long-term outcome. Consulting with your healthcare provider is crucial to determine the best course of action for your individual needs.

Dr. Camel's Conclusion

This study sheds light on the complexities of iron deficiency anemia treatment. It's like choosing a path across the desert - sometimes the fastest route isn't always the best. Both oral ferric maltol and intravenous ferric carboxymaltose offer solutions, but the key is understanding the full picture and choosing the path that best suits your individual needs.
Date :
  1. Date Completed 2022-03-31
  2. Date Revised 2023-11-27
Further Info :

Pubmed ID

33988236

DOI: Digital Object Identifier

PMC8889281

Related Literature

Article Analysis
・Effective treatment of iron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.